Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study.

Autor: Seck SM; Department of Nephrology/Internal Medicine, Faculty of Health Sciences, University Gaston Berger of Saint-Louis, Route de Ngallele, BP 234, Sanar, Saint-Louis, Senegal. sidy-mohamed.seck@ugb.edu.sn.; Dialysis Center, Military Hospital of Ouakam, Dakar, Senegal. sidy-mohamed.seck@ugb.edu.sn.; IRL-ESS-3189, Faculty of Medicine, University Cheikh Anta Diop, Dakar, Senegal. sidy-mohamed.seck@ugb.edu.sn., Mbow M; Dialysis Center, Military Hospital of Ouakam, Dakar, Senegal.; University Cheikh Anta Diop, Dakar, Senegal., Kane Y; University Assane Seck, Ziguinchor, Senegal., Cisse MM; University of Thies, Thiès, Senegal., Faye G; HOGIP, Dakar, Senegal., Kama A; CHR EIN, Kaolack, Senegal., Sarr M; CHR Louga, Louga, Senegal., Nitcheu P; CHR Tamba, Tambacounda, Senegal., Dahaba M; CHN Fawzeyni, Touba, Senegal., Diallo IM; Department of Nephrology/Internal Medicine, Faculty of Health Sciences, University Gaston Berger of Saint-Louis, Route de Ngallele, BP 234, Sanar, Saint-Louis, Senegal., Diawara MS; University of Thies, Thiès, Senegal., Latou LNM; Dialysis Center, Military Hospital of Ouakam, Dakar, Senegal., Dia Y; IRESSEF Diamniadio, Dakar, Senegal., Mboup S; IRESSEF Diamniadio, Dakar, Senegal.
Jazyk: angličtina
Zdroj: BMC nephrology [BMC Nephrol] 2021 Nov 17; Vol. 22 (1), pp. 384. Date of Electronic Publication: 2021 Nov 17.
DOI: 10.1186/s12882-021-02582-w
Abstrakt: Background: Hemodialysis patients are among high-risk groups for COVID-19. Africa is the continent with the lowest number of cases in the general population but we have little information about the disease burden in dialysis patients.
Objectives: This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies in the hemodialysis population of Senegal.
Patients and Methods: We conducted a multicenter cross-sectional survey, between June and September 2020 involving 10 public dialysis units randomly selected in eight regions of Senegal. After seeking their consent, we included 303 patients aged ≥ 18 years and hemodialysis for ≥ 3 months. Clinical symptoms and biological parameters were collected from medical records. Patients' blood samples were tested with Abbott SARS-CoV-2 Ig G assay using an Architect system. Statistical tests were performed with STATA 12.0.
Results: Seroprevalence of SARS-CoV-2 antibodies was 21.1% (95% CI = 16.7-26.1%). We noticed a wide variability in SARS-CoV-2 seroprevalence between regions ranging from 5.6 to 51.7%. Among the 38 patients who underwent nasal swab testing, only six had a PCR-confirmed infection and all of them did seroconvert. Suggestive clinical symptoms were reported by 28.1% of seropositive patients and the majority of them presented asymptomatic disease. After multivariate analysis, a previous contact with a confirmed case and living in a high population density region were associated with the presence of SARS-CoV-2 antibodies.
Conclusion: This study presents to our knowledge the first seroprevalence data in African hemodialysis patients. Compared to data from other continents, we found a higher proportion of patients with SARS-CoV-2 antibodies but a lower lethality rate.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: